Erigeron: A Comprehensive Reference on the Genus, Its Key Species, Chemistry, Traditional Use, and Scientific Evidence
1. Identity and Botanical Classification
Genus and family: Erigeron belongs to the family Asteraceae (also called Compositae — the daisy or composite family). The genus name Erigeron was first published in 1753 and is accepted by World Flora Online; approximately 450–480 species are recognized under the genus as of 2025.
Common names and synonymy: Collectively, members of the genus are known as fleabanes. The most widely studied species carry the following identities:
- Erigeron canadensis L. — commonly called Canadian fleabane or horseweed. This species has at least 35 synonyms, with Conyza canadensis (L.) Cronquist being the most common, and is considered an annual or perennial weed indigenous to both American continents but now widespread around the world.
- Erigeron breviscapus (Vant.) Hand.-Mazz. — known in Chinese medicine as Dengzhanhua (灯盏花), literally "lamp flower" or "shoryscapes daisy." This botanical herb is frequently employed in traditional Chinese medicine in the Yunnan, Hunan, and Guizhou provinces of China; according to the Yunnan Materia Medica, it can increase blood flow, eliminate stagnant blood, unblock meridians, and alleviate pain.
- Erigeron annuus (L.) Pers. — daisy fleabane, a North American annual now widely naturalized in East Asia and Europe.
- Erigeron bonariensis L. (syn. Conyza bonariensis) — hairy fleabane, with a pantropical and subtropical distribution.
- Erigeron floribundus — a species used in Cameroonian and broader African traditional medicine.
- Erigeron acris L. — blue fleabane, a European species used in folk medicine.
Plant morphology: Plants in the genus are distinguished by a well-branched structure, with erect stems (glabrous or hairy) that bear plentiful white, lavender, or pink ray flowers, complemented by yellow disk flowers. The genus is widespread, found in temperate regions across the globe, which has allowed different cultures to incorporate various Erigeron species into their healing traditions.
Common preparations and dosage forms: Erigeron is most commonly prepared as an herbal tea by steeping its dried leaves and flowers in hot water; it is also available as tinctures, capsule supplements, and in topical formulations. In Chinese clinical medicine specifically, the primary extract from E. breviscapus — known as breviscapine — can be prepared into various forms including injection, granules, ordinary tablets, dispersible tablets, capsules, mixture, and drop pills.
2. Traditional and Historical Use
2.1 Indigenous North American Traditions
Native Americans have traditionally used E. annuus to treat coughs, tuberculosis, diarrhoea, dysentery, and cardiovascular problems, and to reduce or stop bleeding, as well as for colds and respiratory illnesses by herbal steam inhalation, reflecting its widespread use in traditional medicine. In the historical eclectic medical tradition, E. canadensis was valued similarly. According to 19th-century eclectic records, key uses included respiratory complaints, cough with mucous discharge, digestion, diarrhea, lack of appetite, kidney and bladder problems, menstrual problems, postpartum bleeding, and capillary or passive hemorrhage; one 19th-century physician found fleabane particularly valuable in passive hemorrhages without fever, especially uterine hemorrhage.
2.2 Traditional Chinese Medicine (TCM)
The whole plant of E. breviscapus has been used in Chinese medicine for more than 600 years due to its broad range of pharmacological effects, including cerebrovascular, cardiovascular, anti-diabetic, anti-inflammatory, antioxidant, and neuroprotective activities. Known as Dengzhanxixin (DZXX), the dried whole plant of E. breviscapus was first published in Materia Medica of South Yunnan by Lan Mao in the Ming Dynasty (1368 AD–1644 AD), and is included in the 2020 edition of the Chinese pharmacopoeia. The use of breviscapine for the treatment of hypertension, cerebral embolism, and paralysis due to cerebrovascular accident dates back to the 1970s. In Traditional Chinese Medicine, the plants of E. acris and E. annuus are widely used in various formulations to treat indigestion, enteritis, epidemic hepatitis, diabetes, hematuria, malaria, and obesity. Erigeron breviscapus has been used by the Yi minority in Southwest China for treating stroke-induced paralysis and rheumatic joint pain.
2.3 European Folk Medicine
In the folk medicine of European countries, the roots of E. acris are applied to alleviate a range of ailments, including toothaches, arthritic pains, bruises, digestive disorders, and enteritis.
2.4 African and Cameroonian Traditions
Erigeron floribundus (Asteraceae) is an herbaceous plant widely used in Cameroonian traditional medicine to treat various diseases of microbial and non-microbial origin. It is a traditional remedy utilized in the treatment of malaria within the folk medicinal traditions of Cameroon and Uganda; it also has multiple traditional uses in African countries, including healing stomach disorders, rheumatism, gout, cystitis, nephritis, dysmenorrhea, dental pains, skin problems, and headaches. In African folk medicine, E. canadensis was used to treat granuloma annulare, ringworm, eczema, sore throats, and urinary tract infections, as well as in medicinal baths.
2.5 South Asian and Pan-Cultural Uses
E. bonariensis is a well-known therapeutic herb in many cultures, employed in the treatment of a wide range of ailments including pain, inflammation, fever, and microbial infections such as urinary tract infections, respiratory tract infections, diarrhea, and dysentery.
3. Key Phytochemical Constituents and Active Compounds
Erigeron has a long history of traditional uses in various ethno-cultures, and occupies an important place in traditional medicines all over the world. The phytochemical profile varies significantly across species, but several major classes of bioactive compounds are identified across the genus.
3.1 Flavonoids and Flavone Glycosides
Phytochemical studies revealed that Erigeron canadensis (syn. Conyza canadensis) contained saponins, diterpenoids, terpenoids, glycosides, tannin, anthraquinone, steroids, and flavonoids.
Scutellarin is the single most important and pharmacologically studied compound in the genus. Scutellarin (SCU) is a flavonoid glycoside compound (4', 5, 6-trihydroxy flavonoid-7-glucuronide) isolated from the traditional Chinese medicine plant Erigeron breviscapus (Vant.) Hand.-Mazz. Breviscapine is a crude extract of several flavonoids of E. breviscapus, containing more than 85% of scutellarin, which has been traditionally used in China as an activating blood circulation medicine to improve cerebral blood supply.
In E. canadensis, a Chinese study identified twelve flavonoids, including quercetin-7-O-beta-D-galactopyranoside, quercetin, luteolin, apigenin, quercetin-3-alpha-rhamnopyranoside, quercetin-3-O-beta-D-glucopyranoside, apigenin-7-O-beta-D-glucopyranoside, luteolin-7-O-beta-D-glucuronide methyl ester, baicalein, and rutin. An earlier study on E. acer aerial parts isolated alpha-amyrin, beta-amyrin, caffeic acid, quercetin, and 4'-hydroxywogonin-7-O-beta-D-glucuronic acid glycoside.
Erigeron annuus, traditionally used to treat disorders such as diabetes and enteritis, contains a variety of chemicals including caffeic acid, flavonoids, and coumarins, providing antifungal and antioxidative benefits. The plant also contains bioactive compounds including flavanones, erigeron flavanones, sesquiterpenoids, ergosterol peroxide, caffeic acid, and pyromeconic acid, among others.
3.2 Essential Oils and Volatile Terpenoids
The essential oil of E. canadensis growing in Japan was found to contain 47 volatile components, of which 91.0% were terpenoid; the main constituents were limonene (31.2%), camphene (14.2%), and germacrene D (11.3%), accounting for 56.7% of the oil; non-terpenoid acetylenic compounds were also detected. The plant is reported to contain erigeron oil, which acts like turpentine but is less irritant and stimulating; the oil consists of d-limonene and terpineol, besides solid dihydrochloride, camphene, and germacrene D. In E. floribundus, the essential oil composition is dominated by spathulenol (12.2%), caryophyllene oxide (12.4%), and limonene (8.8%). For E. breviscapus, β-pinene, 1,8-cineole, thymol, α-terpineol, borneol, eugenol, and nerolidol are found to be the main characteristic terpenoids.
3.3 Phenolic Acids and Caffeoylquinic Acids
The principal preparation of E. breviscapus used in clinical China, DZXX (Dengzhanxixin injection), mainly contains scutellarin, 3,4-di-CQA (caffeoylquinic acid), 3,5-di-CQA, 4,5-di-CQA, caffeic acid, and 5-CQA. Across the genus, caffeic acid and chlorogenic acid are consistently identified as important phenolic acids contributing to antioxidant activity.
3.4 Sterols and Triterpenes
Sphingolipids and their derivatives (β-D-glucopyranoside) were isolated from the ethyl acetate fraction of E. canadensis along with β-sitosterol, stigmasterol, β-sitosterol-3-O-β-D-glucoside, and harmine. In E. floribundus, phytochemical studies showed the presence of over 170 bioactive compounds including coumarins, flavonoids, terpenoids, polyacetylenic compounds, γ-pyrone derivatives, sterols, and various caffeoylquinic acids derived from the essential oil and organic extracts from its various parts.
3.5 Polyphenolic Polysaccharide-Protein Complexes
To investigate the active ingredients in E. canadensis, a complex isolated from flowering parts of the plant was tested for airway defense reflexes, in particular for cough reflexes and airway reactivity, which were experimentally induced by a chemical irritant that simulated the inflammatory conditions of their formation. This polyphenolic polysaccharide-protein (PPP) complex has emerged as a distinct category of bioactive material within the species.
4. Mechanisms of Action
4.1 Cardiovascular and Vascular Mechanisms (Scutellarin / Breviscapine)
Many studies in different animals and cell models have provided evidence for the protective effects of scutellarin because of its antioxidant, antiapoptotic, anti-inflammatory, and calcium channel antagonist properties. Research showed that E. breviscapus flavones could significantly inhibit ADP, arachidonic acid (AA), and platelet activating factor (PAF) from forming into a thrombus; scutellarin could also prevent thrombosis and platelet aggregation and improve haemorheology by restricting the ADP-induced platelet aggregation rate in rats in a dose-dependent manner.
Scutellarin, a major flavonoid of E. breviscapus, has been shown to offer beneficial effects on cardiovascular and cerebrovascular functions; in vitro, scutellarin was found to induce proliferation of human umbilical vein endothelial cells (HUVECs), a dramatic increase in cell migration was measured by wound healing assay, and significantly more invading cells were found in scutellarin-treated groups.
4.2 Anti-inflammatory Mechanisms
Anti-inflammatory effects across the genus have been determined due to high amounts of limonene, (E)-β-ocimene, lachnophyllum ester, and germacrene D in the essential oils; antimicrobial properties of the oils were conditioned by appreciable quantities of limonene, β-pinene, 1,8-cineole, carvacrol, thymol acetate, β-eudesmol, caryophyllene and its oxide, allo-aromadendrene, α-humulene, farnesene, carvacrol, and eugenol. Scutellarin has demonstrated efficacy in modulating multiple biological pathways, including antioxidant, anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms.
4.3 Neuroprotective Mechanisms
Studies in several Alzheimer's disease (AD) models have shown that E. breviscapus and its active ingredients (scutellarin and caffeoylquinic acid) could improve learning and memory ability, with mechanisms associated with inhibiting amyloid β (Aβ) production, aggregation, fibrosis, and neurotoxicity; regulating the cholinergic nervous system; inhibiting oxidative stress and inflammation; inhibiting tau hyperphosphorylation; improving mitochondrial function; and resisting neuronal apoptosis.
Scutellarin, purified from E. breviscapus, has been reported to prevent Alzheimer's disease by affecting Aβ assembly; given the low brain uptake rate of scutellarin, the microbiota-gut-brain axis may be a potential route by which scutellarin prevents AD.
Scutellarin is a major flavone derived from Herba Erigerontis, a Chinese medicine derived from E. breviscapus, which has been shown to possess both estrogenic and neuroprotective properties; scutellarin showed estrogenic effects by activating the estrogen responsive elements and phosphorylation of estrogen receptor alpha in cultured MCF-7 cells in a dose-dependent manner.
4.4 Antitussive and Airway Mechanisms
Pharmacological tests on the polyphenolic polysaccharide-protein complex of E. canadensis revealed an antitussive effect; its activity was most pronounced in comparison with all previously tested compounds from other medicinal plants and approached the effect of codeine, the most potent antitussive used in clinical practice; the results provide the scientific basis for the application of this herb in traditional medicine.
4.5 Antioxidant Mechanisms
E. canadensis is known to possess a broad set of pharmacological effects because of the content of various antioxidants, antiplatelet, and anticoagulant compounds. Skin regeneration and antifungal properties have been related to germacrene D within the essential oil fraction.
5. Scientific Evidence by Area of Use
5.1 Cardiovascular Disease
Evidence type: Human clinical trials, meta-analyses, and in vitro/animal studies — moderate quality in Chinese clinical literature, mostly preliminary globally.
E. breviscapus is the main component of a Chinese herbal drug that has been used to treat cardiovascular diseases in China for a long time; various preparations of scutellarin are still widely used clinically to treat cardiovascular diseases such as hypertension, angina pectoris, coronary heart disease, and stroke.
EBHM (E. breviscapus) is an herbal TCM that has been used to treat cardiovascular and nervous system diseases for more than 600 years; several case-control and randomized controlled studies have shown that EBHM has a good therapeutic effect on stable and unstable angina, acute myocardial infarction, essential hypertension, atrial fibrillation, heart failure, pulmonary heart disease, and acute hypertensive cerebral hemorrhage.
Recent studies have suggested that breviscapine can be used to treat cerebral infarction and diabetic nephropathy; a meta-analysis of randomized and quasi-randomized controlled trials comparing breviscapine plus routine therapy with routine therapy alone showed a statistically significant benefit, with a marked neurologic improvement.
However, there is a need for high-quality, large-sample, randomized clinical trials to further validate these conclusions.
In a preclinical study, scutellarin, a compound extracted from E. breviscapus, was found to improve impaired cardiac function in chronic myocardial infarction rats.
5.2 Cerebrovascular Disease and Neuroprotection
Evidence type: Animal models, in vitro studies, limited clinical data — preliminary to moderate in aggregate.
Scutellarin has demonstrated efficacy in modulating multiple biological pathways including antioxidant, anti-inflammatory, anti-apoptotic, and vasodilatory mechanisms, making it a valuable compound in treating chronic diseases such as cerebrovascular diseases, cardiovascular diseases, neurodegenerative disorders, and metabolic diseases; despite its multi-targeted effects, SCU faces challenges such as low bioavailability and limited clinical data, which hinder its widespread therapeutic application.
In a middle cerebral artery occlusion (MCAO) model in rats, DZXX (E. breviscapus injection) administration ameliorated pathological changes and neuronal loss, reduced reactive oxygen species (ROS) and malondialdehyde (MDA), while increasing superoxide dismutase (SOD); DZXX has also been shown to improve the Barthel index and neurological deficit scores without adverse effects.
5.3 Ophthalmology / Glaucoma
Evidence type: One randomized double-blind clinical trial (small, n=40) — preliminary.
A prospective, randomized, double-blind, clinical trial published in Drugs in R&D (2010) evaluated the visual field protective effect of E. breviscapus extract (EBHM). Forty patients (40 eyes) with primary open-angle glaucoma, visual field defects, and a postsurgical intraocular pressure (IOP) of <18 mmHg were enrolled; EBHM or placebo tablets were given orally according to the randomized and double-blind principle, with two tablets taken three times a day for a period of 6 months; patients were examined every 2 months. After 6 months of EBHM treatment, mean defect (MD) was significantly decreased and mean sensitivity (MS) was significantly increased compared with pre-treatment; the authors concluded that EBHM extract may have a partial protective effect on the visual field of glaucoma patients with controlled IOP. All patients completed the trial, and no obvious adverse effects were found during the treatment period. This is a single small trial and its conclusions require confirmation in larger studies.
5.4 Alzheimer's Disease and Cognitive Function
Evidence type: Animal models, in vitro cell studies, limited clinical reports — highly preliminary; no robust human RCTs.
Current studies have shown that scutellarin, baicalin, and caffeoylquinic acid (CQA), the main components of EBHM, have good pharmacological effects and research prospects in treating cognitive dysfunction; mechanisms include reducing Aβ toxicity, inhibiting tau phosphorylation, providing anti-inflammatory response, regulating the central cholinergic system, resisting oxidative stress, providing anti-apoptosis activity, and promoting nerve cell proliferation and differentiation.
One clinical report found that DZSM (Dengzhan Shengmai) capsules can improve cognitive function and the living capacity of patients with AD; animal model studies suggest that EBHM and its active ingredients (scutellarin and CQA) may improve learning and memory ability through mechanisms associated with inhibition of Aβ aggregation, regulation of the cholinergic nervous system, inhibition of oxidative stress and inflammation, alleviation of tau hyperphosphorylation, and resistance to neuronal apoptosis. However, robust human RCT evidence for Alzheimer's disease specifically remains lacking.
5.5 Antimicrobial Activity
Evidence type: In vitro laboratory studies only — no clinical trials in humans.
The essential oil of E. floribundus showed good activity against Staphylococcus aureus (inhibition zone diameter of 14 mm, minimum inhibitory concentration of 512 µg/mL). In vitro biological activities displayed by the essential oil obtained from the aerial parts of E. floribundus include antioxidant, antimicrobial, and antiproliferative activities; researchers also investigated inhibitory effects on nicotinate mononucleotide adenylyltransferase (NadD) and Trypanosoma brucei, the protozoan responsible for Human African trypanosomiasis.
Pharmacological studies showed that E. canadensis exerted antimicrobial, antioxidant, anticoagulant, anti-inflammatory, anticancer, mutagenic gastric protective effect, and skin depigmentation activity — though it must be noted that all of these findings are from pre-clinical laboratory and animal studies.
5.6 Antiviral Activity
Evidence type: In vitro and animal model studies — preliminary.
Erigeron plants are known to exhibit antiviral activities, including those against the respiratory syncytial virus (RSV); in traditional medicine, E. annuus has been used in the treatment of pulmonary diseases and acute infectious hepatitis. Different in vitro drug administration methods were employed to investigate the impact of the E. annuus ethyl acetate extract (EAE) on various stages of RSV activity including virus inactivation, adsorption inhibition, entry, and replication; the therapeutic efficacy of the extract against RSV infection was evaluated in a mouse model, considering lung index, viral load, and lung tissue histopathology; additionally, the antiviral mechanism was explored using ELISA and RT-qPCR analysis. Individual flavonoids present in E. annuus — apigenin, kaempferol, quercetin, and luteolin — have each been found effective against various respiratory viruses in laboratory settings. No human clinical antiviral trials have been published for Erigeron species.
5.7 Antidiabetic and Metabolic Effects
Evidence type: Animal models and in vitro — preliminary; no human clinical trials confirmed.
E. annuus has been utilized in traditional medicine for the treatment of dyspepsia, enteritis, hepatitis, and hematuria; it is a rich source of various bioactive compounds including flavanones, erigeron flavanones, sesquiterpenoids, ergosterol peroxide, caffeic acid, and pyromeconic acid; the plant has been assessed for potential antidiabetic properties in zebrafish with pancreatic islet damage arising from insulin resistance. Modern research provides scientific evidence showing that extracts or active compounds of E. annuus have antimicrobial, anti-inflammatory, antioxidant, antiatherosclerotic, antidiabetic, and antiobesity effects, though these are based on preclinical models.
5.8 Anti-inflammatory and Analgesic Effects
Evidence type: Animal models and in vitro — preliminary.
Pharmacological studies demonstrated that various extracts and compounds of E. annuus exhibit antifungal, anti-atherosclerosis, anti-inflammatory, antidiabetic, phytotoxic, cytoprotective, antiobesity, and antioxidant activities. Gut modulator effects of E. bonariensis have been identified in animal studies that explain its traditional use in constipation and diarrhea.
5.9 Antitussive and Respiratory Effects
Evidence type: Animal/preclinical pharmacological studies — preliminary.
A polyphenolic polysaccharide-protein complex was isolated from flowering parts of E. canadensis and tested for airway defense reflexes, in particular cough reflexes and airway reactivity, both experimentally induced by a chemical irritant simulating the inflammatory conditions of their formation. Pharmacological tests revealed a significant antitussive effect; its activity was most pronounced in comparison with all previously tested compounds from other medicinal plants and approached the effect of codeine, the most potent antitussive used in clinical practice. This study was preclinical and the finding has not yet been confirmed in human trials.
5.10 Cosmetic and Skin Applications
Evidence type: In vitro cell studies — preliminary.
There are few reports on the functionality of E. annuus water extracts in skin inflammation and barrier protection; one study assessed the therapeutic properties of the extract of EA without roots and its primary ingredient, pyromeconic acid (PA), focusing on their antihistamine, anti-inflammatory, and antioxidative capabilities using HMC-1 (human mast cells) and human keratinocytes (HaCaT cells).
6. Body Systems and Health Areas Associated with Erigeron
Based on the peer-reviewed literature, the following body systems are associated with Erigeron research:
- Cardiovascular system: Blood pressure, platelet aggregation, thrombosis, angina, myocardial infarction, arrhythmia, heart failure, lipid profile.
- Cerebrovascular system: Stroke, cerebral ischemia, cerebral hemorrhage, neuroprotection, cognitive function.
- Neurological / neurodegenerative: Alzheimer's disease, tau pathology, Aβ aggregation, cholinergic regulation.
- Ophthalmological: Glaucoma, visual field protection, retinal neuroprotection.
- Respiratory: Cough suppression, antitussive, airway reactivity, antiviral (RSV), traditional use in pulmonary diseases.
- Gastrointestinal: Diarrhea, enteritis, dyspepsia, gastric ulcer protection, constipation.
- Metabolic / endocrine: Antidiabetic effects, insulin resistance, obesity, hepatitis, liver protection.
- Renal and urological: Kidney disease, diabetic nephropathy, urinary tract infections.
- Dermatological and antimicrobial: Skin inflammation, barrier protection, anti-itch (antihistamine), antimicrobial against bacterial and fungal pathogens.
- Hematological: Passive hemorrhage, anticoagulant and antiplatelet activity, haemorheology.
7. Dosage Forms and Dosages Reported in Studies
The following dosages and dosage forms appear in the identified literature, stated only as reported in those sources:
- Oral tablets (E. breviscapus extract/EBHM) for glaucoma: Two tablets of EBHM or placebo were taken three times a day for a period of 6 months in the published randomized clinical trial.
- Oral infusion (E. canadensis, historical eclectic standard): Standard infusion of 2–4 fluid ounces, up to four times a day.
- Injectable breviscapine preparations: Both purified scutellarin and plant extract mainly containing scutellarin had been successfully used in China in clinical settings. Specific injection dosages per vial or infusion are determined within Chinese clinical protocols and were not uniformly reported across the reviewed sources.
- Pharmacokinetics: Pharmacokinetic studies have shown that the active components of DZXX have a low bioavailability and a high elimination rate in vivo; its utilization can be improved through liposome preparation and combination with other drugs.
- Breviscapine multi-form availability: Breviscapine, from E. breviscapus, can be prepared into various forms including injection, granules, ordinary tablets, dispersible tablets, capsules, mixture, and drop pills.
Note: No standardized internationally approved dosage exists for any Erigeron species as a dietary supplement outside of Chinese regulatory frameworks. Dosages referenced in sources are for informational documentation of study conditions only.
8. Safety Considerations and Known Interactions
8.1 Allergenicity — Asteraceae/Compositae Sensitivity
Erigeron is a member of the Asteraceae family, a group with a well-established potential to cause allergic contact dermatitis. The Asteraceae species have been identified to produce numerous secondary metabolites, such as polyphenols, flavonoids, diterpenoids, and sesquiterpene lactones (SLs), dissolved or suspended in the latex sap or placed in specific trichomes found on plant organs. The main group of chemicals relevant to causing allergies and systemic contact dermatitis are sesquiterpene lactones — lactones with an α-methylene group on the γ-lactone ring. Skin contact with E. canadensis can cause contact dermatitis in some individuals; people with sensitivity to plants in the Asteraceae family should be cautious.
8.2 Cross-Reactivity within Asteraceae
Over 200 species within the Asteraceae family are important causes of contact dermatitis worldwide. Individuals sensitive to the Asteraceae family, such as ragweed, might develop skin rash or respiratory symptoms upon exposure to Erigeron products.
8.3 Antiplatelet and Anticoagulant Interactions
Horseweed (E. canadensis) may slow the blood clotting process and increase the risk of bleeding and bruising. Given that breviscapine from E. breviscapus has documented antiplatelet effects through inhibition of ADP-induced aggregation, concurrent use with anticoagulants (warfarin, heparin) or antiplatelet drugs (aspirin, clopidogrel) represents a potential pharmacodynamic interaction to consider.
8.4 Toxicology — Acute and Subacute Studies
Acute and subacute toxicity studies have shown that DZXX (E. breviscapus) is a safe medicinal material widely used in clinical settings. For E. annuus, no side effects or toxicity have been reported for the plant in the published literature reviewed, prompting researchers to develop a suitable dosage form. These conclusions are based on short-term experimental and observational data and do not preclude long-term adverse effects that have not yet been studied.
8.5 Pharmacokinetic Limitations
Despite its multi-targeted effects, scutellarin faces challenges such as low bioavailability and limited clinical data, which hinder its widespread therapeutic application.
8.6 Tannin-Related Interactions
The tannin content of several Erigeron species — historically recognized as including gallic acid and tannins — carries the potential for interference with the absorption of iron and certain drugs, consistent with the general pharmacological behavior of dietary tannins. Among its constituents, according to historical eclectic analysis, are bitter extractive, tannin, gallic acid, and volatile oil.
8.7 Gaps in Safety Data
The overall safety profile of Erigeron species for use as dietary supplements in Western populations is not well-characterized. There are no comprehensive human safety studies or large-scale pharmacovigilance data outside of the Chinese clinical literature for breviscapine. Further in-depth studies are needed to determine the medical uses of E. annuus and its chemical constituents, pharmacological activities, and clinical applications. Evidence for the safety and efficacy of most species is limited to in vitro and animal studies, and the quality of the clinical evidence is generally low to moderate.
References
Go back